Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold On Portola Phase 2A Trial Evaluating Zetomipzomib
ReutersJul 15, 2025 8:52 PM
July 15 (Reuters) - Kezar Life Sciences Inc KZR.O:
KEZAR LIFE SCIENCES ANNOUNCES FDA HAS LIFTED PARTIAL CLINICAL HOLD ON PORTOLA PHASE 2A TRIAL EVALUATING ZETOMIPZOMIB FOR THE TREATMENT OF PATIENTS WITH AUTOIMMUNE HEPATITIS
KEZAR LIFE SCIENCES INC - TO REQUEST FDA LIFT HOLD ON ZETOMIPZOMIB IN LN
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
[Reuters Analysis] Trump boxes in Fed with extreme rate cut calls: McGeever
ORLANDO, Florida, July 16 (Reuters) - While almost no one thinks Donald Trump's verbal attacks on Federal Reserve Chair Jerome Powell are a positive development, they have electrified the debate about whether the U.S. president is right that interest rates are too high.Reuters
8 hours ago
Bitcoin Price Forecast: Trends and Investment Outlook from 2025 to 2030
From $0.01 in 2009 to $120,000+ in 2025, Bitcoin has evolved from obscurity to a globally recognized financial asset. While institutions and governments increasingly embrace it, investors must remain vigilant against volatility, security risks, and scams.TradingKey
Wed, Jul 16
ASML Q2 FY2025 Earnings Review: Strong Growth and High-NA EUV Breakthrough Shadowed by 2026 Uncertainty
ASML Holding N.V. (NASDAQ: ASML) released its Q2 FY2025 earnings on July 16, 2025, exceeding market expectations with robust net sales and net bookings, though the stock fell around 10% due to cautious guidance for 2026 amid geopolitical uncertainties.TradingKey
Mon, Jul 14
TSMC's Q1 2025 Earning: Technological leadership and AI demand drive continued growth in performance
For investors, TSMC's current valuation has not yet fully reflected its growth potential in the AI chip market. It is recommended to pay attention to its progress in 2nm process mass production and CoWoS capacity expansion.TradingKey
Thu, Apr 17
TSMC 2025 Q1 Outlook: AI-Driven Growth and Supply Chain Breakthrough Amid Tariff Pressures
As the world's leading semiconductor foundry, TSMC's Q1 2025 revenue reached NT$839.254 billion, a year-on-year increase of 41.6%, exceeding market expectations and in line with the company's guidance of NT$820 billion to NT$846.24 billion.TradingKey
Tue, Apr 15
Tradingkey
